Assessment of the Risk/Benefit Ratio of Phase II Cancer Clinical Trials by Institutional Review Board (IRB) members

By A.W. Musschenga, R.B. Keus, W.M. Robinson and N.K. Aaronson

Year: 2003

DOI identifier: 10.1093/annonc/mdf209

OAI identifier: oai:dare.ubvu.vu.nl:1871/44197

Provided by: DSpace at VU

Journal:

Download PDF:
_{Sorry, we are unable to provide the full text but you may find it at the
following location(s):}

http://hdl.handle.net/1871/441... (external link)